Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognostic significance of the controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients
Hiroaki Suzuki et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)
Preoperative controlling nutritional status (CONUT) score as a predictor of long-term outcome after curative resection followed by adjuvant chemotherapy in stage II-III gastric Cancer
Xuechao Liu et al.
BMC CANCER (2018)
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
Matthew D. Galsky et al.
EUROPEAN UROLOGY (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multi-institutional Study
Norifumi Harimoto et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Prognostic impact of the Controlling Nutritional Status score following curative nephrectomy for patients with renal cell carcinoma
Yangqin Zheng et al.
MEDICINE (2018)
Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study
Marie Warny et al.
PLOS MEDICINE (2018)
TNF-α and cancer cachexia: Molecular insights and clinical implications
Hetal J. Patel et al.
LIFE SCIENCES (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
EPIDEMIOLOGY OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER IN THE US, EUROPE AND JAPAN
M. Bharmal et al.
VALUE IN HEALTH (2017)
Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma
Gouji Toyokawa et al.
JOURNAL OF THORACIC DISEASE (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study
Takahiro Toyokawa et al.
BMC CANCER (2016)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
T-cell exhaustion in the tumor microenvironment
Y. Jiang et al.
CELL DEATH & DISEASE (2015)
Impact of the Preoperative Controlling Nutritional Status (CONUT) Score on the Survival after Curative Surgery for Colorectal Cancer
Yasuhito Iseki et al.
PLOS ONE (2015)
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
Andreas R. de Biasi et al.
CLINICAL CANCER RESEARCH (2014)
Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy
Matthew D. Galsky et al.
CANCER (2013)
Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy
Andrea B. Apolo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin
Kazutaka Saito et al.
BJU INTERNATIONAL (2012)
Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
Shan Wan et al.
PLOS ONE (2012)
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Douglas G. Altman et al.
PLOS MEDICINE (2012)
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
W. Joost Lesterhuis et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor
Misato Hashizume et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
